Mechanisms of Methotrexate Resistance in Acute Leukemia
Drug resistance limits the effectiveness of methotrexate (MTX) for the treatment of acute leukemia. An increased understanding of the pathways involved in folate metabolism has allowed investigations of the mechanisms of resistance observed in leukemic blasts obtained from patients. Acute lymphocytic leukemia (ALL) was studied for mechanisms of acquired MTX resistance. MTX transport in 27 patients with untreated ALL and 31 patients with relapsed ALL was measured using a previously described competitive displacement assay. Only 13% of the untreated patients were considered to have impaired MTX transport whereas over 70% of the relapsed patients had evidence of impaired MTX transport. Northern analyses and quantitative RT-PCR for the reduced folate carrier (RFC) were performed on the RNA available from the leukemic blasts of 24 patients in whom MTX transport had been measured. Six of 9 samples with impaired MTX transport had decreased RFC expression (one had no detectable RFC expression), while three had no decrease in RFC expression. Acute myelocytic leukemia (AML) was studied to determine the basis of the decreased MTX polyglutamylation. Enzyme kinetics of the enzyme folylpolyglutamate synthetase (FPGS) were studied, demonstrating FPGS in the myeloid cell lines and patient samples had a higher Km for MTX as a substrate than lymphoid cells. Measuring gamma-glutamyl hydrolase enzyme activity allowed a more accurate prediction of steady state levels of MTX polyglutamates. A knowledge of the mechanisms of MTX resistance that occur in leukemic blasts obtained from patients may allow the development of therapeutic strategies to circumvent resistance.
KeywordsFolylpolyglutamate synthetase gamma-glutamyl hydrolase methotrexate reduced folate carrier acute lymphocytic leukemia acute myelocytic leukemia
reduced folate carrier
acute lymphocytic leukemia
acute myelocytic leukemia
Unable to display preview. Download preview PDF.
- 8.Goker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff, Y, Schnieders B, Steinherz P, Tan C, Berman E, Bertino JR. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia and is correlated with p53 gene mutations. Blood 1995, 86, 677–684.PubMedGoogle Scholar
- 9.Trippett T, Schlemmer S, Elisseyeff Y, Goker E, Wachter M, Steinherz P, Tan C, Berman E, Wright JE, Rosowsky A, Schweitzer B, Bertino JR. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 1992, 80, 1158–1162.PubMedGoogle Scholar
- 12.Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, Meltzer PS, Cowan KH. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995, 55, 3790–3795.PubMedGoogle Scholar
- 15.Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997, 89, 1013–1018.PubMedGoogle Scholar
- 20.Longo GSA, Gorlick R, Tong WP, Lin S, Steinherz P, Bertino JR. ((-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Onc Res 1997, 9, 259–263.Google Scholar
- 33.Mauritz R, Bekkenk M, Pieters R, Veerman AJP, Peters GJ, Jansen G. Resistance to methotrexate and sensitivity for novel antifolates in different types of childhood leukemia. Blood 1994, 84, 45a.Google Scholar